
Sign up to save your podcasts
Or


Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content:
By JAMA Network4.6
162162 ratings
Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content:

38,210 Listeners

43,619 Listeners

27,059 Listeners

136 Listeners

319 Listeners

543 Listeners

701 Listeners

505 Listeners

6,464 Listeners

303 Listeners

269 Listeners

3,369 Listeners

22 Listeners

13 Listeners

8 Listeners

7 Listeners

20 Listeners

30 Listeners

90 Listeners

517 Listeners

375 Listeners

17 Listeners

377 Listeners